Suppr超能文献

载体化 DNA 拓扑异构酶 II 抑制剂 F14512 中的 DNA 结合多胺部分改变了随后酶联 DNA 双链断裂的可修复性。

The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.

机构信息

Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.

Pierre Fabre Research Institute, CRDPF, Toulouse Cedex, France.

出版信息

Mol Cancer Ther. 2017 Oct;16(10):2166-2177. doi: 10.1158/1535-7163.MCT-16-0767. Epub 2017 Jun 13.

Abstract

Poisons of topoisomerase II (TOP2) kill cancer cells by preventing religation of intermediate DNA breaks during the enzymatic process and thus by accumulating enzyme-drug-DNA complexes called TOP2 cleavage-complex (TOP2cc). F14512 is a highly cytotoxic polyamine-vectorized TOP2 inhibitor derived from etoposide and currently in clinical trials. It was shown that F14512 has acquired DNA-binding properties and that the stability of TOP2cc was strongly increased. Paradoxically, at equitoxic concentrations in cells, F14512 induced less DNA breaks than etoposide. Here, we directly compared etoposide and F14512 for their rates of TOP2cc production and resolution in human cells. We report that targeting of TOP2α and not TOP2β impacts cell killing by F14512, contrary to etoposide that kills cells through targeting both isoforms. Then, we show that despite being more cytotoxic, F14512 is less efficient than etoposide at producing TOP2α cleavage-complex (TOP2αcc) in cells. Finally, we report that compared with TOP2αcc mediated by etoposide, those generated by F14512 persist longer in the genome, are not dependent on TDP2 for cleaning break ends from TOP2α, are channeled to a larger extent to resection-based repair processes relying on CtIP and BRCA1 and promote RAD51 recruitment to damaged chromatin. In addition to the addressing of F14512 to the polyamine transport system, the properties uncovered here would be particularly valuable for a therapeutic usage of this new anticancer compound. More generally, the concept of increasing drug cytotoxicity by switching the repair mode of the induced DNA lesions via addition of a DNA-binding moiety deserves further developments. .

摘要

拓扑异构酶 II(TOP2)抑制剂通过阻止酶促过程中中间 DNA 断裂的重新连接,从而积累称为 TOP2 断裂复合物(TOP2cc)的酶-药物-DNA 复合物,杀死癌细胞。F14512 是一种源自依托泊苷的高度细胞毒性聚胺载体 TOP2 抑制剂,目前正在临床试验中。研究表明,F14512 具有 DNA 结合特性,并且 TOP2cc 的稳定性大大增加。矛盾的是,在细胞中达到等效毒性浓度时,F14512 诱导的 DNA 断裂比依托泊苷少。在这里,我们直接比较依托泊苷和 F14512 在人细胞中产生和解析 TOP2cc 的速率。我们报告说,靶向 TOP2α而不是 TOP2β会影响 F14512 的细胞杀伤作用,这与通过靶向两种同工型杀死细胞的依托泊苷相反。然后,我们表明,尽管 F14512 的细胞毒性更强,但它在细胞中产生 TOP2α 断裂复合物(TOP2αcc)的效率不如依托泊苷。最后,我们报告说,与依托泊苷介导的 TOP2αcc 相比,F14512 产生的 TOP2αcc 在基因组中持续时间更长,不需要 TDP2 从 TOP2α 上清除断裂末端,更倾向于依赖 CtIP 和 BRCA1 的基于切除的修复过程,并且促进 RAD51 募集到受损的染色质。除了 F14512 靶向多胺转运系统之外,这里发现的特性对于这种新型抗癌化合物的治疗用途特别有价值。更一般地说,通过添加 DNA 结合部分来改变诱导的 DNA 损伤的修复模式来增加药物细胞毒性的概念值得进一步发展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验